Acquiring Company
Samfara
Acquired Company
Chr. Olesen Synthesis
Greater London
Capital Region Of DenmarkBiotechnologyVenture CapitalLife ScienceManufacturingBiotechnologyPharmaceuticalDescription
Samfara has completed the acquisition of Chr. Olesen Synthesis, marking its first investment in the life sciences sector. Chr. Olesen Synthesis specializes in controlled-substance APIs and aims to expand its capabilities and markets under Samfara's ownership. This acquisition is supported by various institutional investors and represents a strategic move for both companies.
Fundz sees it the moment Samfara makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Chr. Olesen Synthesis?
Chr. Olesen Synthesis was acquired by Samfara, based in Greater London. The deal was reported on October 2, 2026. Samfara is a London-based private equity firm focused on majority buyouts of European life sciences companies in the lower mid-market. Samfara is privately held and operates in Biotechnology.
When did Samfara acquire Chr. Olesen Synthesis?
Samfara's acquisition of Chr. Olesen Synthesis was reported on October 2, 2026. Samfara has completed the acquisition of Chr. Olesen Synthesis, marking its first investment in the life sciences sector. Chr. Olesen Synthesis specializes in controlled-substance APIs and aims to expand its capabilities and markets under Samfara's ownership. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Chr. Olesen Synthesis do?
Chr. Olesen Synthesis is a Danish developer and manufacturer of active pharmaceutical ingredients (APIs) and advanced intermediates, specialising in controlled substances. It is privately held, operating in Manufacturing, and is based in Capital Region Of Denmark.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.